Therapeutic approaches to tardive dyskinesia. A review of the literature.
D018663:Adrenergic Agents / Q000627:therapeutic use; D000978:Antiparkinson Agents / Q000627:therapeutic use; D001480:Basal Ganglia Diseases / Q000139:chemically induced / Q000188:drug therapy / Q000628:therapy; D001923:Brain Chemistry / Q000187:drug effects; D003778:Dentures; D004298:Dopamine / Q000378:metabolism; D018492:Dopamine Antagonists; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D007049:Iatrogenic Disease; D007211:Indoles / Q000627:therapeutic use; D001523:Mental Disorders / Q000188:drug therapy; D009069:Movement Disorders / Q000139:chemically induced / Q000188:drug therapy / Q000453:epidemiology / Q000628:therapy*; D009493:Neurosurgery; D010640:Phenothiazines / Q000627:therapeutic use; D010879:Piperazines / Q000627:therapeutic use; D012075:Remission, Spontaneous; D013577:Syndrome; D014149:Tranquilizing Agents / Q000009:adverse effects / Q000627:therapeutic use; D014364:Tryptophan / Q000627:therapeutic use
D018663:Adrenergic Agents; D000978:Antiparkinson Agents; D018492:Dopamine Antagonists; D006993:Hypnotics and Sedatives; D007211:Indoles; D010640:Phenothiazines; D010879:Piperazines; D014149:Tranquilizing Agents; D014364:Tryptophan; D004298:Dopamine